论文部分内容阅读
Much more complex pharmacokinetic (PK) properties including a nonlinear pharmacokinetics and a significant variation in individual PK process were gradually exhibited by monoclonal antibody (mAb) drugs compared to those typically associated with small-molecule drugs, and the complex PK process of mAb drugs can not be appropriately described by traditional PK models1-3.